The FDA has approved medications that fall into two categories: drugs that change disease progression in people living with early Alzheimer's disease, and drugs that may temporarily mitigate some symptoms of Alzheimer's dementia. Join us for a conversation on the differences between the two classes of medications, treatment efficacy, and review future medications being developed in clinical trial.

Dr. Maryam Beigi is the Associate Director of the Katherine and Benjamin Kagan Alzheimer's Disease Treatment Development Program at the Mary S. Easton Center for Alzheimer's Research and Care at UCLA. Dr. Beigi's specializes in Neurology, Alzheimer's Disease, Dementia, and Memory Disorders.

Dr. Mary Norman is board certified in internal medicine and geriatric medicine with 25-years of experience practicing geriatric and internal medicine. She obtained her medical degree, residency and fellowship training in geriatrics at the University of California, San Francisco. Dr. Norman’s specific areas of interest and expertise include cognitive evaluation, diagnosis and treatment of dementia. VIEW FLYER